Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab response and macular vessel density in diabetic macular edema
IRCT20220416054548N1Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in diabetic macular edema (DME), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Association between bevacizumab response and macular vessel density. Started May 2022; status: completed.
02
Drugs
bevacizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on IRCT20220416054548N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220416054548N1.